

Remarks

By way of this Preliminary Amendment, claims 1-6, 8-11, and 14 are pending. Claims 7, 12, and 13 have been cancelled, and claims 3-6 and 9-11 have been amended. New claim 14 has been added. These claim cancellations, amendments, and additions are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments and additions.


Conclusion

Applicants believe that the subject matter of the pending claims is patentable and that the instant application should accordingly be allowed. If the Examiner believes that a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned attorney at (203) 812-6450.

If there are any fees due in connection with the filing of this application, please charge the fees to undersigned's Deposit Account No. 13-3372.

Respectfully submitted,

Dated: January 31, 2005

  
Susan M. Pellegrino  
Attorney for Applicants  
Reg. No. 48,972

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
(Tel) (203) 812-6450  
(Fax) (203) 812-6459